// App-Quantinova.ai

FRI0026 : PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY

Researchers

Presenter

  • T. Sornasse

Principal Investigators

  • I. H. Song

  • T. Radstake

  • I. Mcinnes

Medical Centers

  • AbbVie Immunology Clinical Development, North Chicago, United States of America

  • AbbVie Immunology Clinical Development, North Chicago, United States of America

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Active Comparator

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved